17beta-hydroxysteroid dehydrogenase type 5 inhibitor ASP9521

{
  "id": "MLC-T-ONC-009518",
  "term": "17beta-hydroxysteroid dehydrogenase type 5 inhibitor ASP9521",
  "field": "Oncology and biomedicine",
  "definition": "A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.",
  "synonyms": [
    "17βHSD5 inhibitor ASP9521",
    "17bHSD5 Inhibitor ASP9521"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/17beta-hydroxysteroid-dehydrogenase-type-5-inhibitor-asp9521/"
}